BiographyDr. Januzzi has been a member of the Massachusetts General Hospital Cardiology Division since 2000 where he is now the Director of the Cardiac Intensive Care Unit and the Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine. He is also Professor of Medicine at Harvard Medical School.
Dr. Januzzi graduated first in his class from New York Medical College in 1994, and subsequently did a residency in Internal Medicine at the Brigham and Women's Hospital, followed by a cardiology and echocardiography fellowship at Massachusetts General Hospital. Since joining the staff at MGH, Dr. Januzzi is an active clinician, with a focus on acute myocardial infarction, chronic coronary artery disease, acute heart failure, chronic heart failure, and aortic disease. He is an active teacher, and has a busy research program, with a specific focus on cardiac biomarker testing. He has published more than 400 manuscripts, and has edited 3 textbooks, and speaks widely on the topic of biomarker testing in heart disease. He has served as the Cardiology Consultant to the Boston Red Sox since 2005.
Dr. Januzzi has an active, world-recognized program in cardiac biomarker testing. His main area of interest focuses on the natriuretic peptides are markers of heart failure diagnosis, prognosis, and management.
Dr. Januzzi has published more than 300 peer reviewed publications, more than 100 review articles and book chapters and has edited three text books.
At age 81, Roman W. DeSanctis, MD, is one of the hospital’s most veteran and most beloved physicians. To honor the legendary MGH cardiologist, the Roman W. DeSanctis, MD, Endowed Distinguished Scholar in Medicine has been established through the generosity of donor Joan Fu and several others.
It was a perfect slide into second base. Keith Harris was safe – but a small abrasion on his left leg would prove otherwise.
Levels of a biomarker used in the diagnosis of heart attacks are almost universally elevated in patients who have undergone coronary-artery bypass grafting (CABG) and, when markedly elevated, powerfully predict the risk of complications.
Adding regular testing for blood levels of a biomarker of cardiac distress to standard care for the most common form of heart failure may significantly reduce the incidence of cardiovascular complications, a new MGH study finds.
Phone 2: 617-726-3443